Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream for BCC Recurrence Following Curettage
NCT00129519Phase 3Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Jan 2004
- Primary completion
- Jan 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imiquimod in basal cell carcinoma (BCC), sponsored by Graceway Pharmaceuticals. Primary endpoint: Number of subjects with recurrence at 1 year. Started Jan 2004; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00129519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00129519.